ArticleNature communications2022
Molecular mechanism of the wake-promoting agent TAK-925.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- In Silico to In Cerebro-Development of the Orexin Receptor Antagonist "Photorexant" for Photomodulation In Vitro and in Mouse Brains.Angewandte Chemie (International ed. in English) · 2026Article
- Molecular Determinants of G Protein Subtype-Specific Coupling to the Angiotensin II Type 1 Receptor.bioRxiv : the preprint server for biology · 2026Article
- Prioritizing neuroactive ligands using motif-guided virtual discovery and zebrafish profiling.npj drug discovery · 2026Article
- Prioritizing Neuroactive Ligands Using Motif-Guided Virtual Discovery and Zebrafish Profiling.bioRxiv : the preprint server for biology · 2026Article
- The orexin system as a pharmacological target in inflammation: peripheral mechanisms and safety implications.Frontiers in pharmacology · 2026Review
- Targeting the Orexin System in the Pharmacological Management of Insomnia and Other Diseases: Suvorexant, Lemborexant, Daridorexant, and Novel Experimental Agents.International journal of molecular sciences · 2025Review
- Alluring Potential to Accelerate Emergence and Ameliorate Opioid-induced Respiratory Depression without Antagonizing Analgesia: Danavorexton Enters the Anesthetic Landscape.Anesthesiology · 2025Article
- Predicting oxytocin binding dynamics in receptor genetic variants through computational modeling.npj women's health · 2025Article
- Reply to: The G protein preference of orexin receptors is currently an unresolved issue.Nature communications · 2023Article
- The G protein preference of orexin receptors is currently an unresolved issue.Nature communications · 2023Article
- Molecular mechanism of fatty acid activation of FFAR1.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 5 institutions in 3 countries.
Jie Yin *Department of Biophysics, The University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX, 75390, USA.
Yanyong Kang *Takeda Development Center Americas, Inc, 9625 Towne Centre Drive, San Diego, CA, 92121, USA.
Aaron P McGrath *Takeda Development Center Americas, Inc, 9625 Towne Centre Drive, San Diego, CA, 92121, USA.
Karen ChapmanDepartment of Biophysics, The University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX, 75390, USA.
Megan SjodtTakeda Development Center Americas, Inc, 9625 Towne Centre Drive, San Diego, CA, 92121, USA.
Eiji KimuraTakeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan.
Atsutoshi OkabeTakeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan.
Tatsuki KoikeTakeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan.
Yuhei MiyanohanaTakeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan.
Yuji ShimizuTakeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan.
Rameshu RallabandiDepartment of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Peng LianBioHPC at the Lyda Hill Department of Bioinformatics, The University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Xiaochen BaiDepartment of Biophysics, The University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX, 75390, USA.ORCID http://orcid.org/0000-0002-4234-5686
Mack FlinspachTakeda Development Center Americas, Inc, 9625 Towne Centre Drive, San Diego, CA, 92121, USA. mflinspach@gmail.com.ORCID http://orcid.org/0000-0003-4602-836X
Jef K De BrabanderDepartment of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. jef.debrabander@utsouthwestern.edu.ORCID http://orcid.org/0000-0001-8816-5798
Daniel M RosenbaumDepartment of Biophysics, The University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX, 75390, USA. dan.rosenbaum@utsouthwestern.edu.ORCID http://orcid.org/0000-0002-7174-4993
Takeda (Japan) · JPTakeda (United States) · USThe University of Texas Southwestern Medical Center · USSouthwestern Medical Center · USChinese Institute for Brain Research · CN
Funding
Structural mechanisms of Scap/SREBP signaling in membrane homeostasisR35GM136387 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI Daniel Rosenbaum · 2020 to 2026
$3.0MStructural elucidation and development of agonists for the human orexin receptorsR01NS103939 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI DE BRABANDER, JEF KAREL, ROSENBAUM, DANIEL · 2017 to 2021
$2.2MStructural elucidation and development of agonists for the human orexin receptorsR56NS097594 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI DE BRABANDER, JEF KAREL, ROSENBAUM, DANIEL · 2017 to 2017
$567kNIGMS NIH HHS R35 GM136387NINDS NIH HHS R01 NS103939NINDS NIH HHS R56 NS097594
Abstract
The OX
Indexed as
NarcolepsyWakefulnessCryoelectron MicroscopyHumansOrexin ReceptorsOrexinsReceptors, G-Protein-CoupledOrexin ReceptorsOrexinsReceptors, G-Protein-Coupled
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.